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Letters to the EditorTRANSMISSION OF HUMAN
T-LYMPHOTROPIC VIRUS
TYPE I BY BILATERAL
LIVING-DONOR LOBAR LUNG
TRANSPLANTATION
To the Editor:
Human T-lymphotropic virus type I
(HTLV-I) is an etiologic agent for
adult T-cell leukemia/lymphoma and
HTLV-I–associatedmyelopathy/tropi-
cal spastic paraparesis. Most HTLV-I
infections are attributable to transmis-
sion from mother to child or to sexual
contact later in life, whereas transfu-
sion is perhaps the most efficient
mode of viral transmission. Seropreva-
lence of HTLV-1 among high-risk
populations is 10% to 30% in thesouthern area of Japan, such as Oki-
nawa, and approximately 5% in the
Caribbean region compared with 1%
in Europe and the United States.
There have been several reports of
HTLV-1 transmission in association
with organ transplantation (Table 1).1-4
However, no report describes a trans-
mission of HTLV-1 by lung transplan-
tation. We describe the first case of
HTLV-1 transmission from a seroposi-
tive donor via lung transplantation.
A 38-year-old woman had abnormal
shadows on a chest x-ray at a healthcare
examination. Video-assisted thora-
coscopic surgical lung biopsy was
performed, and usual interstitial pneu-
monia was diagnosed. Despite some
drug treatments, she had dry cough
and dyspnea that gradually worsened.
In 2003, at the age of 42 years, she
was considered eligible for bilateral
living-donor lobar lung transplantation
at Okayama University. The patient
was negative for anti-HTLV-I anti-
body. The younger sister was positive
less than 16 times for anti-HTLV-I an-
tibody. Because the patient’s condition
was severe and deteriorating, she was
considered to be in urgent need of lung
transplantation. In addition, there are
no reports of HTLV-I transmission by
lung transplantation. Therefore, lung
transplantation was performed using
lungs from an elder brother and a youn-
ger sister in August 2003. Before the
transplant, the lungs were flushed with
1LofEuro-Collins solution,whichcon-
sists of 115 mmol/L monopotassium,
10 mmol/L sodium, and 3.6% glucose,
both antegradely and retrogradely.5The patient’s general condition im-
proved after the lung transplantation.
In November 2008, her oxygen sat-
uration was 98% to 99% at room air.
However, serologic follow-up demon-
strated that she had acquired HTLV-I
infection posttransplantation. Antibody
titers were as follows: 256 times after 9
months, more than 8192 times in Au-
gust 2006, 2048 times in April 2008.
Remesar and colleagues1 reported
the first case of HTLV-1 infection
transmitted by organ transplantation
(a child who received a kidney from
her infected mother). The seroconver-
sion was observed 83 days after trans-
plantation. Nakatsuji and colleagues2
described a kidney transplant recipient
who presented with tropical spastic
paraparesis 4 years posttransplanta-
tion. Toro and colleagues3 reported
the transmission of HTLV-1 from
a single donor to 3 organ (2 kidneys
and 1 liver) transplant recipients, who
subsequently developed tropical spas-
tic paraparesis within 2 years post-
transplant.
Although the lungs were pretreated
with preservative solution, transmission
ofHTLV-1 could not be prevented.Ap-
proximately 5 years posttransplant, our
patient demonstrates neither neurologic
nor hematologic evidence of HTLV-I–
related disease. However, this patient
should be followed up for adult T-cell
leukemia/lymphoma and tropical spas-
tic paraparesis.
Satomi Yara, MD, PhDa
Jiro Fujita, MD, PhDa
Hiroshi Date, MD, PhDb,cTABLE 1. Review of the literature about transmission of human T-lymphotropic virus type I after solid-organ transplantation
First author Year Age and sex Organ Clinical features References
Remesar 2000 Daughter Kidney None 1
Nakatsuji 2000 50 M Kidney HTLV-1–associated myelopathy 2
Toro 2003 53 F* Kidney Subacute myelopathy 3
Toro 2003 55 My Kidney Subacute myelopathy 3
Toro 2003 44 Fz Liver Subacute myelopathy 3
Zarranz 2003 54 F* Kidney Myelopathy 4
Zarranz 2003 57 My Kidney Myelopathy 4
Zarranz 2003 44 Fz Liver Myelopathy 4
Yara 2008 42 F Lung None Present report
HTLV, Human T-lymphotropic virus type I. *, y, zThe same patients.
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effects of statins may be an important
biological mechanism underlying this
beneficial effect.
Although the authors did not include
preoperative serum cholesterol levels
in the analysis because they were not
measured in all patients, they specu-
lated that a beneficial effect of a de-
creased serum cholesterol might not
be ruled out.1 However, the study
suggests that higher baseline choles-
terol levels might actually improve
operative outcomes in patients without
coronary artery disease who undergo
cardiac surgery. In fact, baseline total
cholesterol levels of statin-treated pop-
ulations are higher than those of the
general population.2
Critical care literature provides
strong evidence for a survival advan-
tage associated with higher lipid
levels in critically ill surgical patients.3
Furthermore, in surgical patients,
hypocholesterolemia, beyond being
a strong predictor of in-hospital death,
also predicts nosocomial infections
and length of hospital stay.4 In particu-
lar, it has been shown that critically low
cholesterol concentrations in patients
after cardiothoracic surgery are associ-
ated with a significantly increased risk
for mortal outcome.5
Therefore, we suggest that in indi-
viduals studied by Tabata and col-
leagues,1 statin use selected the
healthy statin user or unselected the
unhealthy patients with low choles-
terol.
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Reply to the Editor:
We appreciate the comments from
Mascitelli and colleagues. We have
shown that preoperative statin use is as-
sociated with lower operative mortality
in cardiac surgical patients without coro-
nary artery disease.1 As they pointed out
and as we described in the original arti-
cle,1 serum cholesterol level could be
a potentially confounding factor of the
association between preoperative statin
use and operative outcomes. However,
the effect of baseline hypocholesterole-
mia on operative outcomes in patients
having cardiac surgery remains un-
known. The previous studies, including
ones thatMascitelli and colleagues refer-
enced, did not reveal an effect. In another
study, Horwich and colleagues2 have
shown that lower serumcholesterol level
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HYPERCHOLESTEROLEMIA
IMPROVE OPERATIVE
OUTCOMES IN PATIENTS
WITHOUT CORONARY
ARTERY DISEASE WHO
UNDERGO CARDIAC
SURGERY?
To the Editor:
Tabata and colleagues1 found that
preoperative use of statins was associ-
ated with lower operative mortality in
patients without coronary artery dis-
ease who underwent cardiac valve sur-
gery and suggested that the pleiotropic
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ication. Although the study population
of this study is not patients having sur-
gery, their findings indicate that serum
cholesterol level may be a negative con-
founding factor in our analysis, which
would not affect our conclusion. Further
investigation is necessary to determine
the effect of preoperative statins on oper-
ative outcomes in cardiac surgery.
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